GlobeNewswire

UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky

GlobeNewswire
A securities class action names Unicycive Therapeutics' Chief Executive Officer and Chief Financial Officer as individual defendants under Section 20(a) control person claims, alleging they controlled disclosures telling shareholders a third-party manufacturer had made "significant progress" toward FDA compliance that the Company had never verified through its own inspection A securities class action names Unicycive Therapeutics' Chief Executive Officer and Chief Financial Officer as individual defendants under Section 20(a) control person claims, alleging they controlled disclosures telling shareholders a third-party manufacturer had made "significant progress" toward FDA compliance that the Company had never verified through its own inspection